--- title: "Geron (GERN) news: class action and offering" url: "https://aibio.space/companies/geron/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "GERN class action and offering news: Geron faces Rytelo securities class action and four derivative suits. Geron Corporation (NASDAQ: GERN), United States." --- GERN Geron Corporation NASDAQ · United States # Geron (GERN) news GERN class action and offering news Legal · 2026-08-05 ## [Geron faces Rytelo securities class action and four derivative suits](https://aibio.space/news/geron-faces-rytelo-securities-class-action-four-derivative-suits/) Geron is a defendant in a consolidated securities class action over statements about RYTELO, and four derivative suits repeat the claims. The class action was dismissed without prejudice on March 30, 2026, and a second amended complaint is now under a motion to dismiss. ## Latest Geron news 1. 2026-03-02 Financings [Geron files automatic shelf with $150,000,000 ATM prospectus via TD Cowen](https://aibio.space/news/geron-files-automatic-shelf-150-000-000-atm-prospectus-td-cowen/) The sales agreement pays TD Securities (USA) LLC up to 3.0% of gross proceeds. Geron's stock last sold at $1.65 on February 26, 2026, and the company's 2025 net loss was $83.5 million. 2. 2025-12-16 Distress [Geron begins restructuring, cutting about one-third of its roughly 260 employees](https://aibio.space/news/geron-begins-restructuring-cutting-about-one-third-roughly-260/) Geron Corporation estimates about $18 million in restructuring charges, mostly severance and benefits, and expects the workforce reduction to be substantially complete in the first quarter of 2026. 3. 2025-12-16 Distress [Geron begins restructuring that cuts about one-third of its roughly 260 employees](https://aibio.space/news/geron-begins-restructuring-cuts-about-one-third-roughly-260-employees/) The company estimates about $18 million in restructuring charges, mostly severance and benefits, hitting results in the fourth quarter of 2025 and the first quarter of 2026. 4. 2024-11-07 Mergers [Geron completes $250 million Royalty Pharma and Pharmakon financings](https://aibio.space/news/geron-completes-250-million-royalty-pharma-pharmakon-financings/) Geron drew $125 million under a Pharmakon term loan and took $125 million from Royalty Pharma, in a quarter with a $26.4 million net loss. The release gives no royalty rates or loan interest rate. ## Geron at a glance - **Ticker**: GERN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $62.6 million ### Related companies - [GridAI Technologies](https://aibio.space/companies/gridai-technologies/) NASDAQ: GRDX - [Anavex Life Sciences](https://aibio.space/companies/anavex-life-sciences/) NASDAQ: AVXL - [Solid Biosciences](https://aibio.space/companies/solid-biosciences/) NASDAQ: SLDB - [Alamar Biosciences](https://aibio.space/companies/alamar-biosciences/) NASDAQ: ALMR - [Odyssey Therapeutics](https://aibio.space/companies/odyssey-therapeutics/) NASDAQ: ODTX - [Lineage Cell Therapeutics](https://aibio.space/companies/lineage-cell-therapeutics/) AMEX: LCTX - [UMeWorld](https://aibio.space/companies/umeworld/) OTC: UMEW - [Nascent Biotech](https://aibio.space/companies/nascent-biotech/) OTC: NBIO ### Also on NASDAQ - [Longeveron](https://aibio.space/companies/longeveron/) LGVN - [Decoy Therapeutics](https://aibio.space/companies/decoy-therapeutics/) DCOY - [Alphatec Holdings](https://aibio.space/companies/alphatec/) ATEC - [Ardelyx](https://aibio.space/companies/ardelyx/) ARDX - [Autonomix Medical](https://aibio.space/companies/autonomix-medical/) AMIX - [Amylyx Pharmaceuticals](https://aibio.space/companies/amylyx-pharmaceuticals/) AMLX ## Geron annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$71.4 million](https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/) | [$103.7 million](https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/) | | Net income (loss) | [-$83.5 million](https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/) | [-$174.6 million](https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/) | | Cash from operations | [-$111.0 million](https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/) | [-$218.6 million](https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/) | | Cash and equivalents | [$77.6 million](https://www.sec.gov/Archives/edgar/data/886744/000088674426000037/) | [$79.0 million](https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/) | | Short-term investments | | [$327.6 million](https://www.sec.gov/Archives/edgar/data/886744/000095017025027982/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $62.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Geron Is there a class action against Geron? Our latest story on this, dated Aug 5, 2026: "Geron faces Rytelo securities class action and four derivative suits". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/geron-faces-rytelo-securities-class-action-four-derivative-suits/). Has Geron raised money recently? Our latest story on this, dated Mar 2, 2026: "Geron files automatic shelf with $150,000,000 ATM prospectus via TD Cowen". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/geron-files-automatic-shelf-150-000-000-atm-prospectus-td-cowen/). What is the ticker symbol of Geron? Geron Corporation trades under the ticker GERN on NASDAQ. Where is Geron listed? Geron Corporation is listed on NASDAQ. Our directory also records these other listings: GETTEX:GON; LS:902213; LSE:0IV3; LSX:902213. What is the SEC CIK of Geron? The SEC Central Index Key (CIK) for Geron Corporation is 886744. Its filings are on SEC EDGAR. How many shares does Geron have outstanding? 642,473,409 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Geron listed under? Our directory records Geron Corporation under United States. What does Geron do? Our directory classifies Geron Corporation as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Geron? The ISIN recorded for Geron Corporation is US3741631036. Does aibio.space cover Geron? aibio.space lists Geron Corporation among 2,820 public biotech companies and publishes its news here as stories appear. Where is Geron incorporated? SEC records list its state or country of incorporation as DE. Is Geron profitable? Geron Corporation reported a net loss of $83.5 million for the fiscal year ended Dec 31, 2025, and used $111.0 million of cash in operations, per its annual report to the SEC. How much does Geron spend on research and development? $71.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Geron have? $62.6 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Geron (GERN) stock news? Our latest story on Geron, dated Aug 5, 2026: "Geron faces Rytelo securities class action and four derivative suits". Geron is a defendant in a consolidated securities class action over statements about RYTELO, and four derivative suits repeat the claims. The class action was dismissed without prejudice on March 30, 2026, and a second amended complaint is now under a motion to dismiss. [Source](https://aibio.space/news/geron-faces-rytelo-securities-class-action-four-derivative-suits/). ## Investor discussion: Geron Members talk about Geron (GERN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Geron, newest first. Each line links the filing it comes from. 1. 2026-03-02 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/886744/000119312526084228/d118024ds3asr.htm) 2. 2025-12-16 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). [Source](https://www.sec.gov/Archives/edgar/data/886744/000088674425000074/gern-20251210.htm) 3. 2025-08-06 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/886744/000088674425000052/gern-20250630.htm) 4. 2025-05-07 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/886744/000088674425000010/gern-20250331.htm) 5. 2024-11-07 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,2.02,2.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/886744/000095017024122771/gern-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:GERN on TradingView](https://www.tradingview.com/symbols/NASDAQ-GERN/). ## SEC filings and registration - **SEC name**: Geron Corp - **CIK**: 886744 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: GERN (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404 - **Phone**: 6504737700 - **Shares outstanding**: 642,473,409 as of 2026-07-31 (10-Q filed 2026-08-05) - **Former names**: GERON CORPORATION ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/886744/000119312526336508/d158179d8k.htm) filed 2026-08-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/886744/000088674426000037/gern-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/886744/000119312526241842/d76653d8k.htm) filed 2026-05-27 - [10-Q](https://www.sec.gov/Archives/edgar/data/886744/000088674426000032/gern-20260331.htm) filed 2026-05-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm) filed 2026-04-07 - [8-K](https://www.sec.gov/Archives/edgar/data/886744/000119312526125151/d192220d8k.htm) filed 2026-03-26 - [10-K](https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/gern-20251231.htm) filed 2026-03-02 - [8-K](https://www.sec.gov/Archives/edgar/data/886744/000119312526068523/d67820d8k.htm) filed 2026-02-25 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000886744), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Geron Corporation is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GERN, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Geron Corporation - **Ticker**: GERN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US3741631036 - **Other listed symbols**: GETTEX:GON; LS:902213; LSE:0IV3; LSX:902213 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-GERN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/geron/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Geron (GERN) news: class action and offering", 2026-10-31, https://aibio.space/companies/geron/